John Newman

Stock Analyst at Canaccord Genuity

(2.18)
# 2,854
Out of 5,044 analysts
84
Total ratings
46.58%
Success rate
-5.06%
Average return

Stocks Rated by John Newman

Regeneron Pharmaceuticals
Oct 23, 2025
Maintains: Buy
Price Target: $850
Current: $654.48
Upside: +29.87%
Delcath Systems
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $10.15
Upside: +106.90%
Merus
Sep 30, 2025
Downgrades: Hold
Price Target: $67$97
Current: $94.89
Upside: +2.22%
Seres Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $14$22
Current: $17.16
Upside: +28.21%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.26
Upside: +1,011.11%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $105.03
Upside: +63.23%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $15.21
Upside: +11.77%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.01
Upside: +692.08%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20$25
Current: $5.60
Upside: +346.43%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85$115
Current: $87.49
Upside: +31.44%
Maintains: Buy
Price Target: $19$8
Current: $0.86
Upside: +835.02%
Maintains: Buy
Price Target: $38$43
Current: $8.32
Upside: +416.83%
Reiterates: Buy
Price Target: $5
Current: $1.22
Upside: +309.84%
Maintains: Buy
Price Target: $52$44
Current: $43.43
Upside: +1.31%
Maintains: Buy
Price Target: $30$38
Current: $14.67
Upside: +159.03%
Maintains: Buy
Price Target: $12$27
Current: $5.14
Upside: +425.29%
Downgrades: Speculative Buy
Price Target: n/a
Current: $12.63
Upside: -